Health / Health News |
An Aspirin A Day Keep Liver Cancer Away
A new study found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B related liver cancer.
A new study held by the American Association for the Study of Liver Diseases found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer.
Hepatitis B is a viral infection that attacks the liver. HBV can be contracted through contact with an infected person's blood or other bodily fluid, and the infection can either be acute or chronic, Science Daily reported.
Past research suggests that daily aspirin therapy, which is often prescribed to prevent cardiovascular disease, may also prevent the development of cancer. However, clinical evidence is lacking for the effectiveness of aspirin therapy in preventing HBV‐related liver cancer.
Although current antiviral medicines such as nucleos(t)ide analogue therapy could significantly reduce liver cancer risk.
Most HBV carriers are not indicated for antiviral therapy, so another effective way of reducing liver cancer risk needs to be developed.
Aspirin has been investigated to explore its chemopreventive effect in cancers that are related to chronic inflammation, particularly in the prevention of colorectal cancer. However, clinical evidence supporting the chemopreventive effect of aspirin therapy on liver cancer remains limited.
Cumulative incidence of liver cancer in the group treated with aspirin therapy was significantly lower than that in the untreated group in five years. In their multivariate regression analysis, the researchers found aspirin therapy was independently associated with reduced liver cancer risk.
Older age, male gender, cirrhosis and diabetes also were independently associated with an increased risk, but nucleos(t)ide analogue or statin use was associated with a decreased risk. (Tasnim News Agency)